ESTROGEN AND PROGESTERONE-RECEPTOR CONCORDANCE BETWEEN PRIMARY AND RECURRENT BREAST-CANCER
ESTROGEN AND PROGESTERONE-RECEPTOR CONCORDANCE BETWEEN PRIMARY AND RECURRENT BREAST-CANCER
复制标题
DOI：
10.1002/jso.2930570202
复制
发表时间：
1994-10-01
影响因子：
2.5
通讯作者：
DUDA, RB
中科院分区：
文献类型：
--
作者：
LI, BDL;BYSKOSH, A;DUDA, RB
乳腺癌雌激素和孕激素受体状态可以决定治疗方案，并可能提供预后信息。本研究的目的是比较原发性乳腺癌类固醇激素受体状态与复发性乳腺癌的一致性，并确定第二种病变类型（局部复发，第二原发性或转移性病变）和接受的辅助治疗是否改变了受体一致性。本文回顾了1976-1990年83例原发性和复发性乳腺癌雌激素受体（ER）分析的资料。此外，其中32例患者还具有原发性和复发性乳腺癌的孕激素受体（PR）值。通过卡方检验、Student t检验和Wilcoxon符号秩检验进行统计学评价。59/83（71%）例患者的ER一致性（原发性/复发性，p/r）; 18/32（56%）例患者的PR一致性。无论第二个病灶是局部复发、第二原发病灶还是转移病灶，都不影响ER一致性或PR一致性。辅助化疗、激素治疗或放射治疗，无论是单独或联合，都不影响ER或PR的一致性。ER（P+）/（r-）（原发性受体阳性/复发性受体阴性）患者的无病生存期（DFS）明显短于ER（P-）/（r+）患者（27.6 +/- 7.4个月对50.6 +/- 7.6个月，P = 0.04）。PR（p+）/（r-）患者的DFS为28.8 +/- 7.9个月，而PR（p-）/（r+）患者的DFS为46.8 +/- 11.8个月（P = NS）。与ER（p-）/（r+）患者相比，ER（p+）/（r-）患者的DFS显著更短，并且与PR（p-）/（r+）患者相比，PR（p+）/（r-）患者的DFS有缩短的趋势，这可能反映了激素调节的丧失或癌症侵袭性的增加。(C)1994 Wiley-Liss，Inc.
Estrogen and progesterone receptor status in breast cancer can determine therapeutic options and may provide prognostic information. The purpose of this study is to compare the concordance of the primary breast cancer steroid hormone receptor status to that of the recurrent breast cancer and to determine whether the type of second lesion (local recurrence, second primary, or metatastic lesion) and adjuvant therapy received changed the receptor concordance. The records of eighty-three patients with estrogen receptor (ER) analysis available for primary (p) and recurrent (r) breast cancer for 1976-1990 were reviewed. In addition, 32 of these patients also had available progesterone receptor (PR) values for primary and recurrent breast cancers. Statistical evaluation was performed by chi-square, Student's t-test, and Wilcoxon signed-rank test. ER concordance (primary/recurrent, p/r) was identified in 59/83 (71%) patients; PR concordance was identified in 18/32 (56%) patients. Whether the second lesion was a local recurrence, second primary, or a metastatic lesion did not affect ER concordance or PR concordance. Adjuvant chemotherapy, hormonal therapy, or radiation therapy, either alone or in combination, did not affect ER or PR concordance. The disease-free survival (DFS) for patients with ER (P+)/(r-) (primary receptor positive/recurrent receptor negative) was significantly shorter than those with ER (p-)/(r+)(27.6 +/- 7.4 months versus 50.6 +/- 7.6 mo, P = 0.04). The DFS for PR (p+)/(r-) patients was 28.8 +/- 7.9 months compared to the DFS of 46.8 +/- 11.8 months for PR (p-)/(r+) patients (P = NS). A significantly shorter DFS for ER (p+)/(r-) patients compared to ER (p-)/(r+) patients and a trend towards a shorter DFS for PR (p+)/(r-) patients compared to PR (p-)/(r+) patients may reflect a loss of hormonal regulation or an increase in cancer aggressiveness. (C) 1994 Wiley-Liss, Inc.